InChI
1S/C22H29N7O5.2ClH/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12;;/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32);2*1H/t14-,15+,16?,18+,22+;;/m0../s1
InChI key
MKSVFGKWZLUTTO-USYAMCSGSA-N
assay
≥98% (TLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated
color
white to off-white
solubility
methanol: 20 mg/mL, water: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
Quality Level
General description
Prokaryotic and eukaryotic protein synthesis inhibitor. Nucleoside that resembles the aminoacyl-adenylyl terminus of aminoacyl-tRNA and competes for binding to the "A site" of the large ribosomal subunit. Its incorporation into a growing polypeptide results in termination of chain elongation and release of the nascent polypeptidyl-puromycin. Used for selection of mammalian cell lines expressing a transfected pac gene (Streptomyces alboniger), whose product, puromycin acetyltransferase, inactivates the drug via acetylation. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells. Like cycloheximide, puromycin is also used as a general protein synthesis inhibitor in numerous cellular assays.
Protein synthesis inhibitor. Inhibits translation by causing premature release of nascent polypeptide chains. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells.
Puromycin, Dihydrochloride, CAS 58-58-2, is An aminonucleoside antibiotic that inhibits protein synthesis by blocking the translation step and causes premature release of nascent polypeptide chains.
Biochem/physiol Actions
Primary Target
protein synthesis
protein synthesis
Preparation Note
Following reconstitution, sterilize by filtration through a 0.22 µm pore-size filter, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Chow, S.C., et al. 1995. Exp. Cell Res. 216, 149.
Constam, D.B., et al. 1995. J. Biol. Chem.270, 26931.
Wirth, M., et al. 1994. J. Virol.68, 566.
Claeyssens, S., et al. 1993. FEBS Lett.315, 7.
Hechler, U., et al. 1993. Biochem. Biophys. Res. Commun.194, 1305.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Kalpaxis, D.L. and Drainas, D. 1992. Arch. Biochem. Biophys.300, 629.
Shipston, M.J. and Antoni, F.A. 1992. Biochem. Biophys. Res. Commun.189, 1382.
Constam, D.B., et al. 1995. J. Biol. Chem.270, 26931.
Wirth, M., et al. 1994. J. Virol.68, 566.
Claeyssens, S., et al. 1993. FEBS Lett.315, 7.
Hechler, U., et al. 1993. Biochem. Biophys. Res. Commun.194, 1305.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Kalpaxis, D.L. and Drainas, D. 1992. Arch. Biochem. Biophys.300, 629.
Shipston, M.J. and Antoni, F.A. 1992. Biochem. Biophys. Res. Commun.189, 1382.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Harmful (C)
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
540222-25MG: + 540222-100MG: + 540222-0GM: + 540222-10GM: + 540222-MG:
jan
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Rui Chen et al.
BMC medicine, 20(1), 68-68 (2022-02-17)
Genome-wide association studies (GWASs) have identified multiple risk loci for Parkinson's disease (PD). However, identifying the functional (or potential causal) variants in the reported risk loci and elucidating their roles in PD pathogenesis remain major challenges. To identify the potential
Rui Chen et al.
Genome medicine, 14(1), 53-53 (2022-05-20)
Genome-wide association studies (GWASs) have identified multiple risk loci for bipolar disorder (BD). However, pinpointing functional (or causal) variants in the reported risk loci and elucidating their regulatory mechanisms remain challenging. We first integrated chromatin immunoprecipitation sequencing (ChIP-Seq) data from
Ying Huang et al.
Frontiers in physiology, 12, 697139-697139 (2021-09-08)
Our previous study found that acupuncture with low frequency electrical stimulation (Acu/LFES) prevents muscle atrophy by attenuation of protein degradation in mice. The current study examines the impact of Acu/LFES on protein synthesis. C57/BL6 mice received Acu/LFES treatment on hindlimb
Hotaka Kobayashi et al.
Nature communications, 13(1), 1435-1435 (2022-03-19)
MicroRNAs (miRNAs) are small non-coding RNAs, which regulate the expression of thousands of genes; miRNAs silence gene expression from complementary mRNAs through translational repression and mRNA decay. For decades, the function of miRNAs has been studied primarily by ensemble methods
Lei Chang et al.
Journal of molecular neuroscience : MN (2021-10-15)
Following spinal cord injury (SCI), multiple signaling cascades are activated instantaneously in the injured segments of the spinal cord to create a complex and pathogenic microenvironment, making it difficult to treat SCI. Nevertheless, the significance of the integrated stress response
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)